# Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

> **NCT04218266** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 755 (actual)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** BAY2433334
- **DRUG:** Apixaban
- **OTHER:** BAY2433334 matching placebo
- **OTHER:** Apixaban matching placebo

## Key facts

- **NCT ID:** NCT04218266
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 755 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218266, "Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04218266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*